Receptor Targeting Liposomal Nano Formulations for Drug Delivery in Breast Cancer
Recently, incidences of breast cancer are increasing and it has become a leading cause of cancer related deaths of women globally. Though pharmaceutical and biotechnology industries are developing, and researchers are working to find a better treatment of breast cancer patients to improve the effectiveness of current therapy, the survival rate is very low. A lot of research is going on based on lipid particulate systems which has versatile applications for the treatment of life-threatening diseases such as breast cancer. Out of various lipid particulate systems, liposomes have been studied and explored widely as they have many applications such as improving solubility of antitumor drugs, reduces the side effects, long circulation in blood, possibility of passive and active targeting to tumor cells. Liposomal system is most popular because of its biocompatibility, capability to encapsulate hydrophilic as well as hydrophobic drugs, ease of surface modification and wide range of applications. Thus, a thorough research is ongoing for upgradation of liposomes as multipotential carriers and its effective therapeutic. Therefore, this review article includes the recent development and techniques of liposomal nano formulations drug delivery system. This review majorly focuses on the breast cancer and its therapy, current challenges in experimental and clinical studies in liposomal formulations.
1. Patel J, Amrutiya J, Bhatt P, Javia A, Jain M, Misra A. Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells. Journal of Microencapsulation. 2018;35(2):204-17.
2. Yewale C, Baradia D, Patil S, Bhatt P, Amrutiya J, Gandhi R, et al. Docetaxel loaded immunonanoparticles delivery in EGFR overexpressed breast carcinoma cells. Journal of Drug Delivery Science and Technology. 2018;45:334-45.
3. Bhatt P, Khatri N, Kumar M, Baradia D, Misra A. Microbeads mediated oral plasmid DNA delivery using polymethacrylate vectors: an effectual groundwork for colorectal cancer. Drug delivery. 2015;22(6):849-61.
4. Patil S, Bhatt P, Lalani R, Amrutiya J, Vhora I, Kolte A, et al. Low molecular weight chitosan–protamine conjugate for siRNA delivery with enhanced stability and transfection efficiency. RSC Advances. 2016;6(112):110951-63.
5. Hortobagyi GN. Treatment of breast cancer. The New England journal of medicine. 1998;339(14):974-84.
6. Elhazzat J E-SM. Advances in targeted breast cancer therapy. . Curr Breast Cancer Rep 2010;2((3), ):146–51
7. Bhatt P, Narvekar P. Challenges and Strategies for Drug Transport across the Blood Brain Barrier. ARC Journal of Neuroscience. 2018;3(3):17-21.
8. Dhankhar R, Vyas SP, Jain AK, Arora S, Rath G, Goyal AK. Advances in novel drug delivery strategies for breast cancer therapy. Artificial cells, blood substitutes, and immobilization biotechnology. 2010;38(5):230-49.
9. Park JW. Liposome-based drug delivery in breast cancer treatment. Breast cancer research : BCR. 2002;4(3):95-9.
10. Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Critical reviews in therapeutic drug carrier systems. 2009;26(6):523-80.
11. Koning GA, Storm G. Targeted drug delivery systems for the intracellular delivery of macromolecular drugs. Drug discovery today. 2003;8(11):482-3.
12. Voinea M, Simionescu M. Designing of 'intelligent' liposomes for efficient delivery of drugs. Journal of cellular and molecular medicine. 2002;6(4):465-74.
13. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nature reviews Cancer. 2008;8(6):473-80.
14. Sawant RR, Torchilin VP. Liposomes as ‘smart’ pharmaceutical nanocarriers. Soft Matter. 2010;6(17):4026-44.
15. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nature reviews Drug discovery. 2005;4(2):145-60.
16. Fishman DA, Cohen L, Blank SV, Shulman L, Singh D, Bozorgi K, et al. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. American journal of obstetrics and gynecology. 2005;192(4):1214-21; discussion 21-2.
17. Marchetti C, Pisano C, Facchini G, Bruni GS, Magazzino FP, Losito S, et al. First-line treatment of advanced ovarian cancer: current research and perspectives. Expert review of anticancer therapy. 2010;10(1):47-60.
18. Johnson SW, Ozols RF, Hamilton TC. Mechanisms of drug resistance in ovarian cancer. Cancer. 1993;71(2 Suppl):644-9.
19. Dinarvand R, Varshochian R, Kamalinia G, Goodarzi N, Atyabi F. Recent approaches to overcoming multiple drug resistance in breast cancer using modified liposomes2013. 391-4 p.
20. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer control : journal of the Moffitt Cancer Center. 2003;10(2):159-65.
21. Zhou T, Duan J, Wang Y, Chen X, Zhou G, Wang R, et al. Fluoxetine synergys with anticancer drugs to overcome multidrug resistance in breast cancer cells. Tumour Biol. 2012;33(5):1299-306.
22. Seelig A, Gerebtzoff G. Enhancement of drug absorption by noncharged detergents through membrane and P-glycoprotein binding. Expert opinion on drug metabolism & toxicology. 2006;2(5):733-52.
23. Lao J, Madani J, Puertolas T, Alvarez M, Hernandez A, Pazo-Cid R, et al. Liposomal Doxorubicin in the treatment of breast cancer patients: a review. Journal of drug delivery. 2013;2013:456409.
24. Kulkarni PR YJ, Vaidya KA. . Liposomes: a novel drug delivery system. Int J Curr Pharm Res. 2011; 3((2)):10–8
25. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends in pharmacological sciences. 2009;30(11):592-9.
26. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Advanced drug delivery reviews. 2013;65(1):36-48.
27. Dua J RA, Bhandari A. . Liposome: methods of preparation and applications. . Int J Pharm Stud Res 2012;3(2):14–20
28. Sharma G, Anabousi S, Ehrhardt C, Ravi Kumar MN. Liposomes as targeted drug delivery systems in the treatment of breast cancer. Journal of drug targeting. 2006;14(5):301-10.
29. Rivera E. Liposomal anthracyclines in metastatic breast cancer: clinical update. The oncologist. 2003;8 Suppl 2:3-9.
30. Bhatt P, Lalani R, Vhora I, Patil S, Amrutiya J, Misra A, et al. Liposomes encapsulating native and cyclodextrin enclosed paclitaxel: Enhanced loading efficiency and its pharmacokinetic evaluation. Int J Pharm. 2018;536(1):95-107.
31. Gabizon AA. Liposomal anthracyclines. Hematology/oncology clinics of North America. 1994;8(2):431-50.
32. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer research. 1994;54(4):987-92.
33. Gabizon AA, Shmeeda H, Zalipsky S. Pros and cons of the liposome platform in cancer drug targeting. Journal of liposome research. 2006;16(3):175-83.
34. Tandel H, Bhatt P, Jain K, Shahiwala A, Misra A. In-Vitro and In-Vivo Tools in Emerging Drug Delivery Scenario: Challenges and Updates. In: Misra ASA, editor. In-vitro and in-vivo tools in drug delivery research for optimum clinical outcomes. Boca Raton: CRC Press; 2018.
35. Atyabi F, Farkhondehfai A, Esmaeili F, Dinarvand R. Preparation of pegylated nano-liposomal formulation containing SN-38: In vitro characterization and in vivo biodistribution in mice. Acta pharmaceutica (Zagreb, Croatia). 2009;59(2):133-44.
36. J. OS. Liposomal anthracyclines for breast cancer: overview. . The oncologist. 2003;8(Suppl. 2 ):1–2
37. Lalani RA, Bhatt P, Rathi M, Misra A. Abstract 2063: Improved sensitivity and in vitro efficacy of RGD grafted PEGylated gemcitabine liposomes in RRM1 siRNA pretreated cancer cells. Cancer research. 2016;76(14 Supplement):2063.
38. Rom J, Bechstein S, Domschke C, Golatta M, Mayer C, Heil J, et al. Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer. Anti-cancer drugs. 2014;25(2):219-24.
39. Pathak Nandish PP. Applications of liposome in cancer drug delivery and treatment: A review Asian Journal of Pharmaceutical Research and Development. 2019;7(1):62-5.
40. Vhora I, Patil S, Bhatt P, Gandhi R, Baradia D, Misra A. Receptor-targeted drug delivery: current perspective and challenges. Therapeutic delivery. 2014;5(9):1007-24.
41. Bhatt P, Vhora I, Patil S, Amrutiya J, Bhattacharya C, Misra A, et al. Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status. Journal of Controlled Release. 2016;226:148-67.
42. Vhora I, Patil S, Bhatt P, Misra A. Protein- and Peptide-drug conjugates: an emerging drug delivery technology. Advances in protein chemistry and structural biology. 2015;98:1-55.
43. Egusquiaguirre SP, Igartua M, Hernandez RM, Pedraz JL. Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2012;14(2):83-93.
44. Low PS, Henne WA, Doorneweerd DD. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Accounts of chemical research. 2008;41(1):120-9.
45. Kularatne SA, Low PS. Targeting of nanoparticles: folate receptor. Methods in molecular biology (Clifton, NJ). 2010;624:249-65.
46. Bhatt P, Lalani R, Mashru R, Misra A. Abstract 2065: Anti-FSHR antibody Fab’ fragment conjugated immunoliposomes loaded with cyclodextrin-paclitaxel complex for improved in vitro efficacy on ovarian cancer cells. Cancer research. 2016;76(14 Supplement):2065.
47. Kikumori T, Kobayashi T, Sawaki M, Imai T. Anti-cancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes. Breast cancer research and treatment. 2009;113(3):435-41.
48. Gao J, Zhong W, He J, Li H, Zhang H, Zhou G, et al. Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes. Int J Pharm. 2009;374(1-2):145-52.
49. Barrajon-Catalan E, Menendez-Gutierrez MP, Falco A, Carrato A, Saceda M, Micol V. Selective death of human breast cancer cells by lytic immunoliposomes: Correlation with their HER2 expression level. Cancer letters. 2010;290(2):192-203.
50. Drummond DC, Noble CO, Guo Z, Hayes ME, Connolly-Ingram C, Gabriel BS, et al. Development of a highly stable and targetable nanoliposomal formulation of topotecan. Journal of controlled release : official journal of the Controlled Release Society. 2010;141(1):13-21.
51. Gao J, Liu W, Xia Y, Li W, Sun J, Chen H, et al. The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. Biomaterials. 2011;32(13):3459-70.
52. Gomes-da-Silva LC, Santos AO, Bimbo LM, Moura V, Ramalho JS, Pedroso de Lima MC, et al. Toward a siRNA-containing nanoparticle targeted to breast cancer cells and the tumor microenvironment. Int J Pharm. 2012;434(1-2):9-19.
53. Kullberg M, McCarthy R, Anchordoquy TJ. Gene delivery to Her-2+ breast cancer cells using a two-component delivery system to achieve specificity. Nanomedicine : nanotechnology, biology, and medicine. 2014;10(6):1253-62.
54. Govindarajan S, Sivakumar J, Garimidi P, Rangaraj N, Kumar JM, Rao NM, et al. Targeting human epidermal growth factor receptor 2 by a cell-penetrating peptide-affibody bioconjugate. Biomaterials. 2012;33(8):2570-82.
55. Shroff K, Kokkoli E. PEGylated liposomal doxorubicin targeted to alpha5beta1-expressing MDA-MB-231 breast cancer cells. Langmuir : the ACS journal of surfaces and colloids. 2012;28(10):4729-36.
56. Moghimi SM, Hunter AC. Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. Trends in biotechnology. 2000;18(10):412-20.
57. Park EK, Lee SB, Lee YM. Preparation and characterization of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs. Biomaterials. 2005;26(9):1053-61.
58. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urologic oncology. 2008;26(1):57-64.
59. Mansour AM, Drevs J, Esser N, Hamada FM, Badary OA, Unger C, et al. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer research. 2003;63(14):4062-6.
60. Nomura T, Saikawa A, Morita S, Sakaeda Kakutani T, Yamashita F, Honda K, et al. Pharmacokinetic characteristics and therapeutic effects of mitomycin C-dextran conjugates after intratumoural injection. Journal of controlled release : official journal of the Controlled Release Society. 1998;52(3):239-52.
61. Prabha S, Labhasetwar V. Nanoparticle-mediated wild-type p53 gene delivery results in sustained antiproliferative activity in breast cancer cells. Molecular pharmaceutics. 2004;1(3):211-9.